JAMA Oncol 7 (8): 1121-1123, 2021.[PUBMED Abstract] Tutt ANJ, Garber JE, Kaufman B, et al.: Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
N Engl J Med 384 (25): 2394-2405, 2021.[PUBMED Abstract] Mittendorf EA, Jeruss JS, Tucker SL, et al.: Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy.
J Clin Oncol 29 (15): 1956-62, 2011.[PUBMED Abstract] Ganz PA, Bandos H, Španić T, et al.: Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.